Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Feb 2017
Multicenter StudyPhase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
Eribulin, a microtubule dynamics inhibitor, is approved for the treatment of patients with breast cancer and soft tissue sarcoma. We investigated the efficacy and safety of eribulin in Japanese patients with soft tissue sarcoma. ⋯ Eribulin showed clinical activity with a manageable safety profile in previously treated Japanese patients with advanced/metastatic soft tissue sarcoma.